Metagenomics for Ocular Inflammation
Key facts
- Who runs it
- Moorfields Eye Hospital NHS Foundation Trust
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 36 people, planned
- Started
- 12 Jun 2025
- Expected to end
- 27 Nov 2027
- Type of study
- Observational
- Treatments tested
- Metagenomic sequencing of aqueous humor
- Ocular Imaging
- Record updated
- 21 July 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- 18 years of age or older with the capacity to consent
- Standard of care has not determined a clinical diagnosis
- Active ocular inflammation with risk of visual loss
- Clinically suspected infectious or para-infectious cause of ocular inflammation
Who cannot take part
- Contraindication to ocular fluid sampling
- Where an urgent result within 5 days is clinically required
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to apply a diagnostic test called 'metagenomic sequencing' to identify the involvement of potential infections in patients with ocular inflammation, where this hasn't been detected by currently available standard testing. For many people with ocular inflammation, no cause is ever found for their disease. In some cases, an infection or infectious trigger is suspected, but currently available tests are inadequate. Metagenomic sequencing can identify almost every globally known infection (bacteria, virus, fungi, parasites) in a sample. Therefore, it has the potential to identify an infection that has caused or triggered ocular inflammation, and as a consequence may help to identify specific treatments. It has the potential to improve our understanding of how to diagnose and treat people with this problem. This study will allow us to test the technique that has been previously optimised for brain infections, on ocular fluids. Participants will be 18 years of age or over and have active ocular inflammation which is suspected to be due to an infection, or an autoimmune process which has been triggered by an infection, but identification of this infection has not been possible using the investigations available as part of standard NHS care. Participants will be identified by the treating clinical team as requiring a sample of fluid from inside of the eye, and some of this fluid will be sent for metagenomic sequencing alongside standard testing. This study will be conducted at Moorfields Eye Hospital, London and will last for approximately a year. Participants will undergo additional non-invasive ocular imaging on the day of their clinic visit, but will not have to attend any additional research visits.
The group in the trial
- Patients with ocular inflammation presumed to be infectious or para-infectious
Patients with Ocular Inflammation undergoing Metagenomics on Aqueous Humour
Treatment: Metagenomic sequencing of aqueous humor and Ocular Imaging
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Metagenomic Sequencing of Ocular Fluids in Patients With Ocular Inflammation
- Record updated
- 21 July 2026